Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui

Agreement represents strong strategic fit that leverages the company’s internal DNA damage response expertise and in-house ADC capabilities

02-Nov-2023 - Merck announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) ...

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success

20-Sep-2023 - Merck announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., ...

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology

Merck shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity

22-Nov-2022 - To achieve the goal of introducing one new product or major indication every 1.5 years on average, the company will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an ...

Merck and Artios will conduct collaborative research

Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

03-Dec-2020 - Merck and Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs. “Our platform has ...

Merck to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group

03-May-2018 - Merck announced a development agreement for investigational molecule abituzumab with SFJ Pharmaceuticals Group (SFJ), a US-based company focused on increasing R&D output and productivity through innovative models. “Our collaboration with SFJ illustrates Merck’s increasing focus on strategic ...

Merck creates immuno-oncology spin out iOnctura

Initial capital provided by Merck Ventures

21-Jun-2017 - Merck announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). CRT is the commercial arm of ...

Merck Licenses Four Oncology Research and Development Programs from Vertex

Vertex receives upfront payment of $230 million plus royalties on future sales

12-Jan-2017 - Merck announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Inc. for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.“With this strategic deal we ...

Merck and Pfizer to present Avelumab data in seven different cancers

Data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers

20-May-2016 - Merck and Pfizer announced that avelumab presentations across seven different tumor types, including two oral presentations, will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting. The avelumab presentations, from the rapidly accelerating JAVELIN clinical development ...

Merck Appoints Maya Martinez-Davis as Global Head of Oncology

18-Apr-2016 - Merck announces the appointment of Maya Martinez-Davis (46), as Global Head of Oncology Franchise for its biopharma business. She will report to Rehan Verjee, Chief Marketing and Strategy Officer of Merck’s Healthcare business sector, and will be based in Billerica, Massachusetts, USA. In her new ...